Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.

Autor: de Oliveira JK; Departamento de Medicina Veterinária, Universidade Federal do Paraná (UFPR), Curitiba, Brazil., Williams DL; Department of Veterinary Medicine, University of Cambridge, Cambridge, UK., Bollmann C; Departamento de Medicina Veterinária, Universidade Federal do Paraná (UFPR), Curitiba, Brazil., de Seabra NM; Departamento de Medicina Veterinária, Universidade Federal do Paraná (UFPR), Curitiba, Brazil., Bortolini M; Departamento de Medicina Veterinária, Universidade Federal do Paraná (UFPR), Curitiba, Brazil., Montiani-Ferreira F; Departamento de Medicina Veterinária, Universidade Federal do Paraná (UFPR), Curitiba, Brazil.; Department of Small Animal Clinical Sciences, Michigan State University, Veterinary Medical Center, East Lansing, Michigan.
Jazyk: angličtina
Zdroj: Veterinary ophthalmology [Vet Ophthalmol] 2019 Sep; Vol. 22 (5), pp. 633-643. Date of Electronic Publication: 2019 Feb 06.
DOI: 10.1111/vop.12634
Abstrakt: Objective: To assess the efficacy of 0.1% oclacitinib as a single agent, and in combination with tacrolimus 0.01%, for the control of ophthalmic signs of keratoconjunctivitis sicca (KCS) in dogs.
Animals Studied: Thirty-two dogs (57 eyes) diagnosed with idiopathic KCS were included. Inclusion criteria were Schirmer Tear Test 1 (STT-1) values <15 mm/min and concurrent clinical signs such as ocular hyperemia and discharge.
Procedures: The animals were submitted to a randomized, open-label, 5-week study and divided into 3 treatment groups treated with the following ophthalmic solutions: (a) 0.1% oclacitinib, (b) 0.1% oclacitinib +0.01% tacrolimus, and (c) 0.01% tacrolimus. Eye drops were instilled twice daily (12-hour intervals). At each follow-up examination, STT-1, clinical signs, and potential drug side effects were assessed.
Results: Oclacitinib did not significantly improve STT-1 values or clinical scores. Tacrolimus alone and in combination with oclacitinib increased mean STT-1 values by 11.84 ± 5.2 and 12.46 ± 5.3 mm/min, respectively (P = 0.0001). Clinical scores of ocular discharge and hyperemia also improved significantly in both groups receiving treatment with tacrolimus (P < 0.05). However, addition of oclacitinib to tacrolimus provided no additional improvement over tacrolimus alone.
Conclusions: Topical 0.1% oclacitinib twice daily is not effective in controlling the ocular signs of KCS in dogs. 0.01% tacrolimus increased STT-1 values significantly and could potentially be used as a treatment for mild-to-moderate cases of KCS. Synergism between drugs did not occur, and therefore the use of oclacitinib is not justified in cases of canine KCS.
(© 2019 American College of Veterinary Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz: